Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Re Agreement

24th Jun 2005 07:00

International Medical Devices PLC24 June 2005 International Medical Devices plc Acquisitions and Fundraising International Medical Devices plc announces today that it has entered into aconditional agreement to acquire a series of rights from two Australiancompanies which, together with a fund raising exercise, has a transactionalvalue for IMD of £8.4 million on completion. The agreement comes at the same time as the completion of a placing of OrdinaryShares at 6 pence per share to raise £750,000 before expenses. The Company now intends to embark on a programme of acquisitions which areintended to grow IMD as a leading supplier of safe medical devices. The Company's conditional agreements are to acquire Technology Patents for arange of medical devices from Eastland Technology Australia Limited ("ETA") andto acquire from Eastland Medical Systems Limited ("EMS") exclusive DistributionRights over a range of EMS's medical devices products. The consideration forthe acquisition of the Technology Patents is to be satisfied by the payment of£300,000 in cash and the issue to ETA of 55,160,000 new Ordinary Shares,representing approximately 44.43% of the enlarged issued share capital of IMD.The consideration for the acquisition of the Distribution Rights is to besatisfied by the issue to EMS of 40,500,000 new Ordinary Shares, representingapproximately 32.62% of the enlarged issued share capital of IMD. These acquisitions will therefore constitute a reverse takeover within themeaning of the AIM Rules and, as required by those rules, is subject to the IMDshareholders' approval. The Company has also completed a placing of Ordinary Shares at 6 pence per shareto raise £750,000 before expenses (approximately £500,000 after expenses). Fromthe net proceeds, £150,000 will be used to satisfy the part of the cash elementof the consideration payable to ETA under the Patent Sale Agreement atCompletion. The balance of £150,000 is to be paid when the IMD Board determinesthat the Company has sufficient surplus available funds and the Company will beobliged to pay the balance from any further capital fundraising. The balance of the net funds raised will allow the Company to pursue itsstrategy to acquire safe medical device businesses and fund its working capitalrequirements. The Company is to issue warrants to placees, under which theywill have the right to subscribe up to £2,825,000 in total for Ordinary Sharesat the next substantial offering of equity capital (whether on an acquisition ora placing) at a price that is 75 per cent of the applicable issue price. IMD is proposing to acquire the Technology Patents from ETA and the DistributionRights from EMS in respect of territories outside the Southern Hemisphere,specifically North America, UK and most of Europe. . ETA is an Australian company that is involved in the development, manufacturingand marketing of a range of products that utilise new technology for injection,infusion and blood drawing. EMS is an Australian company that manufactures and distributes medical devicesproducts, some of which are based on certain of ETA's patents and others that ithas developed itself. IMD proposes to acquire the distribution rights overexisting products manufactured by EMS. IMD's Strategy IMD's objective is to bring its portfolio of products to market as quickly as itis able. Initially, this will require securing the relevant regulatoryapprovals, such as CE Marking in the European Union, both for the existing EMSproducts and for future products derived from the Technology Patents, and thengenerating early commercial sales. The Directors and Proposed Directors intendto target the UK and other European markets first. They believe there is agrowing interest in safe medical devices in Europe, the largest market outsidethe US. Furthermore, Europe's regulatory approval pathway is similar to thatapplied in Australia, where many of EMS's products are already approved. IMD intends to develop its channels to market by acquiring distributors ofmedical devices in the UK and other European countries. A number of suchcompanies have already been identified although no negotiations have yetcommenced. In the longer term, IMD's objectives will be to: • continue to acquire and exploit technology patents and distribution rights of safe medical equipment and devices; • become a global supplier of medical devices; and • develop further its relationships with ETA and EMS. Directors and Proposed Directors Jeremy Friedlander has indicated his intention to step down from the Board as aNon-Executive Director in the near future and the Board will seek a suitablereplacement. The Board is grateful for the contribution made by Mr Friedlanderto the formation of the Company and its flotation on AIM in November last year. On Completion, the Company proposes to appoint Mr Doug Sims and Mr DonO'Sullivan to the Board as Non-Executive Directors, to represent ETA and EMSrespectively. Current trading and prospects Since its admission to AIM, the Company has not actively traded, although theDirectors have begun the process of identifying possible acquisitions and jointventure channels to market arrangements with a number of companies. TheDirectors consider that the acquisition of the Technology Patents andDistribution Rights will be the first step in the development of the Company.The next step will be to put in place channels to market to exploit the value inthese rights. Share option scheme The Company is proposing to establish a share option scheme to motivate andretain its employees and others who contribute to the Company's success. TheDirectors will determine the rules of the scheme, and the grant of options toDirectors, Proposed Directors, employees and others will be at the discretion ofthe remuneration committee of the Directors and Proposed Directors. The numberof Ordinary Shares over which options may be granted is to be limited to 10 percent. of the total number of Ordinary Shares then in issue. It is proposedthat, on Completion, IMD will grant options to Mr Christopher Thomas, one of theDirectors, over 500,000 Ordinary Shares. Admission to AIM Application will be made for the re-admission of the Existing Ordinary Sharesand the admission of the New Ordinary Shares to trading on AIM and it isexpected that Admission will take place and that dealings will commence on 19July 2005. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

Intelliam Ai
FTSE 100 Latest
Value10,422.13
Change-30.55